drug · small molecule

SUNLENCA

updated 2mo ago

/ LEN-ə-KAP-ə-veer /

by $GILD GILEAD SCIENCES, INC.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hiv-1 infection and 1 investigational indication.

targets

Structural capsid protein

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

SUNLENCA

trade names

Sunlenca

generic

LENACAPAVIR SODIUM

MOA

12.1 Mechanism of Action SUNLENCA is an HIV-1 antiretroviral agent [see Microbiology (12.4) ] .

indication

1 INDICATIONS AND USAGE SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. ( 1 )

SUNLENCA

targets

all catalysts(0)

News(0)

🐶 often sniffed alongside

comments(0)

Report a data issue